MEDIVIR, INTERIM REPORT, 1 January - 30 September 2006

• License agreement signed with Bristol-Myers Squibb for MIV-170 with a total contract value of USD 104.5 m.

• MIV-606 outlicensed to a total contract value of USD 24,5 m and shares in Epiphany Biosciences.

• Phase III study on Lipsovir® (ME-609) against labial herpes started in July, 25% of patients in the study treated in the third quarter.

• Consolidated net sales in 1 January-30 September 2006 totaled SEK 88.1 (41.0) m, of which continuing operations represented SEK 31.8 (41.0) m and discontinued operations SEK 56.3 (0) m.

• The loss after tax amounted to SEK -115.0 (-112.6) m; earnings per share were SEK -8.91 (-8.72).

FOR MORE INFORMATION, PLEASE CONTACT
Rein Piir, CFO and VP, Investor Relations: +46 (0)8 546 83123 or +46 (0)70 853 7292.

FORTHCOMING FINANCIAL INFORMATION
The Financial Statement for 2006 will be published on 14 February 2007.
The Three-month Interim Report will be published on 24 April 2007.
The Annual General Meeting will be held on 24 April 2007.

Medivir’s financial reports are available on its Website, www.medivir.se from these dates under the ‘Investor/Media’ heading.